{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:32:32Z","timestamp":1785353552294,"version":"3.55.0"},"reference-count":91,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Scirrhous-type gastric cancer (SGC) is a rare but well-recognized subset of resectable gastric cancer (GC), accounting for \u205310% of cases. Despite its long history of clinical recognition dating back to the pre-1900s, SGC remains one of the most challenging GC subtypes to treat. Traditionally, SGC has been clinically defined as Borrmann type 4 GC, with histological classifications such as signet ring cell carcinoma or diffuse-type histology serving as alternative diagnostic criteria. Therapeutic advancements for SGC have largely focused on locally advanced or oligometastatic disease, yet no SGC-specific treatment has been established. The phase III JCOG0501 trial failed to demonstrate a survival benefit of neoadjuvant S-1 plus cisplatin for Borrmann type 4 and large type 3 GC. Recent developments in biomarker-driven therapies may redefine SGC by molecular subtypes, with CLDN18.2-targeted therapy emerging as a potential option for some SGC cases. However, as the landscape of medical oncology evolves, SGC may not remain a distinct therapeutic entity. The focus should shift toward understanding the intrinsic biology of SGC. Treatment development for SGC is expected to continue advancing, becoming increasingly stratified based on molecular abnormalities while maintaining a commitment to addressing unmet needs, such as early-onset GC and GC with symptomatic peritoneal dissemination.<\/jats:p>","DOI":"10.1093\/jjco\/hyaf081","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T18:48:47Z","timestamp":1747939727000},"page":"860-870","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic strategy for scirrhous type gastric cancer"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4987-1934","authenticated-orcid":false,"given":"Izuma","family":"Nakayama","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East , Kashiwanoha 6-5-1, Kashiwa, 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"2025080402263837900_ref1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12957-017-1187-3","article-title":"The significance of a nineteenth century definition in the era of genomics: Linitis plastica","volume":"15","author":"Agnes","year":"2017","journal-title":"World J Surg Oncol"},{"key":"2025080402263837900_ref2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","article-title":"Japanese classification of gastric carcinoma: 3rd English edition","volume":"14","author":"Japanese Gastric Cancer A","year":"2011","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12957-016-0805-9","article-title":"Clinicopathologic characteristics and prognosis of Borrmann type IV gastric cancer: A meta-analysis","volume":"14","author":"Luo","year":"2016","journal-title":"World J Surg Oncol"},{"key":"2025080402263837900_ref4","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"2025080402263837900_ref5","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/SLA.0b013e318216f449","article-title":"Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: A summary of 480 cases","volume":"253","author":"Becker","year":"2011","journal-title":"Ann Surg"},{"key":"2025080402263837900_ref6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/s1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): An interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025080402263837900_ref7","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.2217\/fon-2022-0093","article-title":"Josep Tabernero MATTERHORN: Phase III study of durvalumab plus FLOT chemotherapy in resectable gastric\/gastroesophageal junction cancer","volume":"18","author":"Yelena","year":"2022","journal-title":"Future Oncol"},{"key":"2025080402263837900_ref8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s10120-013-0294-2","article-title":"Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-a)","volume":"17","author":"Kurokawa","year":"2014","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10120-014-0401-z","article-title":"Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-a)","volume":"18","author":"Nakamura","year":"2015","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JCO.2020.38.4_suppl.381","article-title":"Surrogate indicators of survival in patients who received neoadjuvant chemotherapy for type 4 and large type 3 gastric cancer in JCOG0501","volume":"38","author":"Terashima","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025080402263837900_ref11","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2217\/fon-2023-0605","article-title":"Randomized phase II study comparing neoadjuvant 5-fluorouracil\/oxaliplatin\/docetaxel versus docetaxel\/oxaliplatin\/S-1 for patients with type 4 or large type 3 gastric cancer","volume":"19","author":"Hashimoto","year":"2023","journal-title":"Future Oncol"},{"key":"2025080402263837900_ref12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s10120-018-0884-0","article-title":"A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: Results of the KDOG1001 trial","volume":"22","author":"Hosoda","year":"2019","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/jjco\/hyaa221","article-title":"Short-term results of a phase II study of preoperative docetaxel\/cisplatin\/S-1 therapy for locally advanced gastric cancer","volume":"51","author":"Tsuchida","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2025080402263837900_ref14","first-page":"58","article-title":"JGCA (the Japan gastric cancer association). Gastric cancer treatment guidelines","volume":"34","author":"Shimada","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"2025080402263837900_ref15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10120-006-0370-y","article-title":"Gastric cancer treated in 1991 in Japan: Data analysis of nationwide registry","volume":"9","author":"Japanese Gastric Cancer Association Registration C","year":"2006","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-012-0163-4","article-title":"Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry","volume":"16","author":"Nashimoto","year":"2013","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"2025080402263837900_ref18","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025080402263837900_ref19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s11605-008-0516-9","article-title":"Borrmann type IV: An independent prognostic factor for survival in gastric cancer","volume":"12","author":"An","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"2025080402263837900_ref20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/jjco\/hyaa005","article-title":"Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives","volume":"50","author":"Terashima","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"2025080402263837900_ref21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10120-008-0496-1","article-title":"Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002)","volume":"12","author":"Kinoshita","year":"2009","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref22","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s10120-024-01546-x","article-title":"Oncological similarities between large type 3 and type 4 tumors in patients with resectable gastric cancer: A propensity score-matched analysis of a multi-institutional dataset","volume":"27","author":"Nakanishi","year":"2024","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/jso.23301","article-title":"Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210)","volume":"107","author":"Iwasaki","year":"2013","journal-title":"J Surg Oncol"},{"key":"2025080402263837900_ref24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","article-title":"Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): An open-label, phase 3, randomized controlled trial","volume":"24","author":"Iwasaki","year":"2021","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1200\/JCO.2019.37.4_suppl.110","article-title":"Subgroup analysis of JCOG0501 phase III study to confirm superiority of additional neoadjuvant chemotherapy with S-1 plus cisplatin to D2 gastrectomy with S-1 adjuvant chemotherapy for resectable type IV or large type III gastric cancer","volume":"37","author":"Katai","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025080402263837900_ref26","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"2025080402263837900_ref27","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N Engl J Med"},{"key":"2025080402263837900_ref28","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s10120-019-00941-z","article-title":"Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan clinical oncology group study (JCOG0501)","volume":"22","author":"Terashima","year":"2019","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","article-title":"Japanese gastric cancer treatment guidelines 2018 (5th edition)","volume":"24","author":"Japanese Gastric Cancer A","year":"2021","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref30","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"2025080402263837900_ref31","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/JCO.2023.41.16_suppl.4067","article-title":"Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial","volume":"41","author":"Kang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025080402263837900_ref32","doi-asserted-by":"publisher","first-page":"102226","DOI":"10.1016\/j.esmoop.2023.102226","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","volume":"9","author":"Shitara","year":"2024","journal-title":"ESMO Open"},{"key":"2025080402263837900_ref33","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1186\/s12885-022-09890-w","article-title":"Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): Protocol of a multi-center, phase II study","volume":"22","author":"Endo","year":"2022","journal-title":"BMC Cancer"},{"key":"2025080402263837900_ref34","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1200\/JCO.2024.42.16_suppl.4031","article-title":"Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial","volume":"42","author":"Miyagaki","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025080402263837900_ref35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12032-024-02583-3","article-title":"Phase I study of neoadjuvant chemoradiotherapy with S-1 for clinically resectable type 4 or large type 3 gastric cancer in elderly patients aged 75 years and older (OGSG1303)","volume":"42","author":"Shinkai","year":"2024","journal-title":"Med Oncol"},{"key":"2025080402263837900_ref36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235666","article-title":"Intraperitoneal chemotherapy as adjuvant or perioperative chemotherapy for patients with type 4 Scirrhous gastric cancer: PHOENIX-GC2 trial","volume":"10","author":"Ishigami","year":"2021","journal-title":"J Clin Med"},{"key":"2025080402263837900_ref37","doi-asserted-by":"publisher","first-page":"100189","DOI":"10.1016\/j.iotech.2022.100189","article-title":"85P Tislelizumab combined with apatinib and oxaliplatin plus S1 as neoadjuvant therapy for Borrmann IV large Borrmann III type and bulky N positive advanced gastric cancer: A single-arm multicenter trial (TAOS-3B-trial)","volume":"16","author":"Chen","year":"2022","journal-title":"Immuno-Oncol Technol"},{"key":"2025080402263837900_ref38","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1080\/14796694.2024.2400042","article-title":"Perioperative systemic and prophylactic intraperitoneal chemotherapy for type 4\/large type 3 gastric cancer: DRAGON-10","volume":"20","author":"Jin","year":"2024","journal-title":"Future Oncol"},{"key":"2025080402263837900_ref39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123081","article-title":"Are Borrmann's types of advanced gastric cancer distinct Clinicopathological and molecular entities? A western study","volume":"13","author":"Diaz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025080402263837900_ref40","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s12029-022-00880-6","article-title":"Borrmann type predicts response to preoperative therapy in advanced gastric cancer","volume":"54","author":"Hirata","year":"2023","journal-title":"J Gastrointest Cancer"},{"key":"2025080402263837900_ref41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.amjsurg.2006.03.004","article-title":"Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer","volume":"192","author":"Saito","year":"2006","journal-title":"Am J Surg"},{"key":"2025080402263837900_ref42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00595-014-1060-8","article-title":"Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer","volume":"45","author":"Hosoda","year":"2015","journal-title":"Surg Today"},{"key":"2025080402263837900_ref43","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","article-title":"Preoperative Chemoradiotherapy for Resectable gastric cancer","volume":"391","author":"Leong","year":"2024","journal-title":"N Engl J Med"},{"key":"2025080402263837900_ref44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/1471-2407-13-281","article-title":"Phase II\/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002","volume":"13","author":"Piessen","year":"2013","journal-title":"BMC Cancer"},{"key":"2025080402263837900_ref45","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2019.37.15_suppl.4019","article-title":"Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19)","volume":"37","author":"Eveno","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025080402263837900_ref46","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1093\/annonc\/mdx275","article-title":"A phase III trial comparing oral S-1\/cisplatin and intravenous 5-fluorouracil\/cisplatin in patients with untreated diffuse gastric cancer","volume":"28","author":"Ajani","year":"2017","journal-title":"Ann Oncol"},{"key":"2025080402263837900_ref47","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1200\/JCO.2019.37.15_suppl.4017","article-title":"S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric\/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial","volume":"37","author":"Xu","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025080402263837900_ref48","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S2468-1253(19)30083-4","article-title":"Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): An open-label, phase 3, randomised controlled trial","volume":"4","author":"Yamada","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025080402263837900_ref49","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/bjc.1991.171","article-title":"Reproducibility of histologic classification of gastric cancer","volume":"63","author":"Palli","year":"1991","journal-title":"Br J Cancer"},{"key":"2025080402263837900_ref50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00268-001-0195-0","article-title":"Differences between biopsy- or specimen-related Laur\u00e9n and World Health Organization classification in gastric cancer","volume":"26","author":"Flucke","year":"2002","journal-title":"World J Surg"},{"key":"2025080402263837900_ref51","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2025080402263837900_ref52","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"2025080402263837900_ref53","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"2025080402263837900_ref54","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJMc2409512","article-title":"Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma","volume":"391","author":"Shitara","year":"2024","journal-title":"N Engl J Med"},{"key":"2025080402263837900_ref55","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","article-title":"Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer","volume":"8","author":"Kubota","year":"2023","journal-title":"ESMO Open"},{"key":"2025080402263837900_ref56","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2025080402263837900_ref57","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10120-021-01235-z","article-title":"The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration","volume":"24","author":"Ooki","year":"2021","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref58","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.7150\/jca.29184","article-title":"Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: A meta-analysis and systemic review","volume":"10","author":"Kim","year":"2019","journal-title":"J Cancer"},{"key":"2025080402263837900_ref59","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/bf01212724","article-title":"Molecular mechanism of stomach carcinogenesis","volume":"119","author":"Tahara","year":"1993","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025080402263837900_ref60","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): A randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025080402263837900_ref61","doi-asserted-by":"publisher","first-page":"TPS4164","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4164","article-title":"Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101)","volume":"40","author":"Smyth","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025080402263837900_ref62","doi-asserted-by":"publisher","first-page":"TPS4165","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4165","article-title":"Trial in progress: Phase 1b\/3 study of bemarituzumab + mFOLFOX6 + nivolumab versus mFOLFOX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102)","volume":"40","author":"Wainberg","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025080402263837900_ref63","doi-asserted-by":"publisher","first-page":"e1736","DOI":"10.1002\/ctm2.1736","article-title":"Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and Claudin-18 isoform 2 splicing variants in gastric cancer and other solid tumours","volume":"14","author":"Katoh","year":"2024","journal-title":"Clin Transl Med"},{"key":"2025080402263837900_ref64","first-page":"8848","article-title":"Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma","volume":"63","author":"Nakazawa","year":"2003","journal-title":"Cancer Res"},{"key":"2025080402263837900_ref65","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3892\/mmr.2013.1397","article-title":"Clinical significance of keratinocyte growth factor and K-sam gene expression in gastric cancer","volume":"7","author":"Tani","year":"2013","journal-title":"Mol Med Rep"},{"key":"2025080402263837900_ref66","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2159-8290.Cd-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic Cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"key":"2025080402263837900_ref67","doi-asserted-by":"publisher","first-page":"115262","DOI":"10.1016\/j.ejca.2025.115262","article-title":"Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications","volume":"218","author":"Satoh","year":"2025","journal-title":"Eur J Cancer"},{"key":"2025080402263837900_ref68","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s43018-021-00240-6","article-title":"Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities","volume":"2","author":"Tanaka","year":"2021","journal-title":"Nat Cancer"},{"key":"2025080402263837900_ref69","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1158\/1538-7445.AM2024-3317","article-title":"Abstract 3317: KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harbouring KRASG12V mutations and KRAS wild-type amplifications","volume":"84","author":"Popow; ATDHPFSLHOSVSDGFSJLCHFRJ","year":"2024","journal-title":"Cancer Res"},{"key":"2025080402263837900_ref70","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10120-022-01353-2","article-title":"Comprehensive transcriptomic profiling and mutational landscape of primary gastric linitis plastica","volume":"26","author":"Liu","year":"2023","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref71","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10120-020-01051-x","article-title":"Development and internal validation of a diagnostic score for gastric linitis plastica","volume":"23","author":"Vivier-Chicoteau","year":"2020","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref72","doi-asserted-by":"publisher","first-page":"1274209","DOI":"10.3389\/fphar.2024.1274209","article-title":"Roles and inhibitors of FAK in cancer: Current advances and future directions","volume":"15","author":"Hu","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025080402263837900_ref73","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2159-8290.Cd-19-0811","article-title":"Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"2025080402263837900_ref74","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ijc.30801","article-title":"Cancer-associated fibroblast-derived Lumican promotes gastric cancer progression via the integrin \u03b21-FAK signaling pathway","volume":"141","author":"Wang","year":"2017","journal-title":"Int J Cancer"},{"key":"2025080402263837900_ref75","doi-asserted-by":"publisher","first-page":"TPS505","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS505","article-title":"Phase 2 trial of defactinib in combination with avutometinib in patients with advanced diffuse-type gastric cancer","volume":"43","author":"Moy","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025080402263837900_ref76","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.exphem.2016.09.002","article-title":"Variegated RHOA mutations in human cancers","volume":"44","author":"Kataoka","year":"2016","journal-title":"Exp Hematol"},{"key":"2025080402263837900_ref77","doi-asserted-by":"publisher","first-page":"23198","DOI":"10.18632\/oncotarget.25269","article-title":"DGC-specific RHOA mutations maintained cancer cell survival and promoted cell migration via ROCK inactivation","volume":"9","author":"Nishizawa","year":"2018","journal-title":"Oncotarget"},{"key":"2025080402263837900_ref78","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/cas.13967","article-title":"Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults","volume":"110","author":"Nakayama","year":"2019","journal-title":"Cancer Sci"},{"key":"2025080402263837900_ref79","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Cancer Genome Atlas Research N","year":"2014","journal-title":"Nature"},{"key":"2025080402263837900_ref80","first-page":"758","article-title":"Gastric linitis plastica is not a surgical disease","volume":"106","author":"Aranha","year":"1989","journal-title":"Surgery"},{"key":"2025080402263837900_ref81","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/SLA.0000000000001814","article-title":"Randomized controlled trial to evaluate splenectomy in Total gastrectomy for proximal gastric carcinoma","volume":"265","author":"Sano","year":"2017","journal-title":"Ann Surg"},{"key":"2025080402263837900_ref82","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S2468-1253(18)30090-6","article-title":"Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): A phase 3, open-label, randomised controlled trial","volume":"3","author":"Kurokawa","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025080402263837900_ref83","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/jjco\/hyaa113","article-title":"Randomized controlled phase III trial to evaluate omentum preserving gastrectomy for patients with advanced gastric cancer (JCOG1711, ROAD-GC)","volume":"50","author":"Sato","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"2025080402263837900_ref84","doi-asserted-by":"publisher","first-page":"LBA4001","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4001","article-title":"Effect of chemotherapy\/targeted therapy alone vs. chemotherapy\/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575\/RENAISSANCE phase III trial","volume":"42","author":"Al-Batran","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025080402263837900_ref85","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1186\/s12885-021-08872-8","article-title":"Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II\/III adenocarcinoma - the phase III \"PREVENT\"- (FLOT9) trial of the AIO \/CAOGI \/ACO","volume":"21","author":"Gotze TO","year":"2021","journal-title":"BMC Cancer"},{"key":"2025080402263837900_ref86","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12885-019-5640-2","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)","volume":"19","author":"Koemans","year":"2019","journal-title":"BMC Cancer"},{"key":"2025080402263837900_ref87","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s10120-020-01137-6","article-title":"Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): A multi-institutional retrospective study","volume":"24","author":"Yamaguchi","year":"2021","journal-title":"Gastric Cancer"},{"key":"2025080402263837900_ref88","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5230\/jgc.2025.25.e11","article-title":"Korean practice guidelines for gastric cancer 2024: An evidence-based, multidisciplinary approach (update of 2022 guideline)","volume":"25","author":"Kim","year":"2025","journal-title":"J Gastric Cancer"},{"key":"2025080402263837900_ref89","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.2025.43.4_suppl.327","article-title":"Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: Results from the multicenter, randomized, phase 3 DRAGON-01 trial","volume":"43","author":"Yan","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025080402263837900_ref90","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12885-023-10680-1","article-title":"Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial","volume":"23","author":"Senthil","year":"2023","journal-title":"BMC Cancer"},{"key":"2025080402263837900_ref91","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2024.08.007","article-title":"Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases","volume":"167","author":"Zhao","year":"2024","journal-title":"Gastroenterology"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/8\/860\/63299154\/hyaf081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/8\/860\/63299154\/hyaf081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T06:26:44Z","timestamp":1754288804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/8\/860\/8140943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":91,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,5,22]]},"published-print":{"date-parts":[[2025,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf081","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,5,22]]}}}